Assessment of LDL-C and triglycerides efficacy of atorvastatin at different starting doses in patients with Type 2 diabetes

被引：0
|
作者：
Hey-Hadavi, J [1 ]
Laskey, R [1 ]
Yurkovic, C [1 ]
Palmer, G [1 ]
机构：
[1] Pfizer Inc, New York, NY USA
来源：
DIABETOLOGIA | 2003年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1026
引用
收藏
页码：A353 / A354
页数：2
相关论文
共 50 条
  • [21] Evolution of LDL-C in Type 1 Diabetes: The SEARCH for Diabetes in Youth Study
    Shah, Amy S.
    Maahs, David M.
    Stafford, Jeanette M.
    Dolan, Lawrence M.
    Lang, Wei
    Imperatore, Giuseppina
    Bell, Ronny A.
    Liese, Angela D.
    Reynolds, Kristi
    Pihoker, Catherine
    Marcovina, Santica M.
    Dabelea, Dana
    DIABETES, 2014, 63 : A158 - A159
  • [22] Sustained postprandial decrease in LDL-Cholesterol (LDL-C) in patients with type-2 diabetes mellitus (T2DM)
    Lund, S
    Petersen, M
    Frandsen, M
    Carstensen, B
    Parving, HH
    Dyerberg, J
    Jensen, T
    DIABETES, 2003, 52 : A213 - A213
  • [23] LDL-C treatment patterns and associated outcomes in patients with type 2 diabetes and CVD: insights from TECOS
    De Ferrari, G. M.
    Stevens, S. R.
    Ambrosio, G.
    Leonardi, S.
    McGuire, D. K.
    Armstrong, P. W.
    Green, J. B.
    Bethel, M. A.
    Holman, R. R.
    Peterson, E. D.
    EUROPEAN HEART JOURNAL, 2018, 39 : 399 - 400
  • [24] Efficacy of simvastatin therapy in attainment of LDL-C and TG goal levels in patients with type 2 diabetic dyslipidemia
    Dobs, Adrian
    Miller, Michael
    DeLucca, Paul T.
    Ramsey, Karen E.
    Tershakovec, Andrew M.
    Horn, Wendy
    JOURNAL OF CLINICAL LIPIDOLOGY, 2008, 2 (01) : 12 - 18
  • [25] Correlation of Circulating Ceramides and LDL-C in Elderly Patients with Coronary Heart Disease and Type 2 Diabetes Mellitus
    Cao, R. H.
    Fang, Z. Y.
    Zhang, J. B.
    Hu, W. C.
    Lu, T. T.
    Fan, L.
    Cao, F.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2023, 71 : S64 - S65
  • [26] Comparison of efficiency between Rosuvastatin and Atorvastatin in reducing low-density lipoprotein (LDL-C) in patients with diabetes mellitus
    Khokhar, Saad Ahmed
    Rehman, Rai Muhammad Farooq Ur
    Masood, Seemal
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2022, 72 (11) : 2288 - 2290
  • [27] Association of Coronary Artery Calcification with MDA-LDL-C/LDL-C and Urinary 8-Isoprostane in Japanese Patients with Type 2 Diabetes
    Ono, Mitsutaka
    Takebe, Noriko
    Oda, Tomoyasu
    Nakagawa, Riyuki
    Matsui, Mizue
    Sasai, Takayoshi
    Nagasawa, Kan
    Honma, Hiroyuki
    Kajiwara, Takashi
    Taneichi, Haruhito
    Takahashi, Yoshihiko
    Takahashi, Kazuma
    Satoh, Jo
    INTERNAL MEDICINE, 2014, 53 (05) : 391 - 396
  • [28] Comparison in effects of atorvastatin on reducing plasma LDL-C between patients with FH and patients with FCHL
    Homma, Y
    Homma, K
    Oguma, T
    Yamaguchi, H
    Ozawa, H
    Fusegawa, Y
    Shiina, Y
    ATHEROSCLEROSIS SUPPLEMENTS, 2003, 4 (02) : 162 - 162
  • [29] Pentraxin 3 level in serum is associated with LDL-C and apo C3 in patients with type 2 diabetes and NAFLD
    Walus, M.
    Idzior-Walus, B.
    Trojak, A.
    Kapusta, M.
    Malecki, M. T.
    DIABETOLOGIA, 2016, 59 : S556 - S556
  • [30] Effectiveness of atorvastatin in treating patients to LDL-C goals compared with lovastatin, pravastatin and simvastatin
    Nawrocki, J
    Shurzinske, L
    Black, DM
    ATHEROSCLEROSIS, 1997, 134 (1-2) : 120 - 120
12345